Oculogica Inc, founded in 2013 and based in New York, specializes in the manufacturing of electro-medical apparatus. The company's core mission is to revolutionize concussion assessment through innovative technology. Their flagship product, EyeBOX®, is the first FDA-cleared concussion assessment tool that does not require a baseline test. EyeBOX® provides immediate and objective insights by measuring abnormalities in eye movements, aiming to improve patient outcomes in concussion diagnosis and management.
Notable affiliated people include leading neuroscientists and medical professionals who contribute to the company's research and development efforts. Oculogica has secured significant investments from prominent venture capital firms and angel investors. Key achievements include receiving FDA clearance for EyeBOX® and establishing partnerships with major healthcare providers. The overall impact of Oculogica lies in its ability to offer a reliable, non-invasive solution for concussion assessment, thereby enhancing clinical decision-making and patient care.
